Menu Search
Equities

Healwell Al Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
HWAIF:QXE

Healwell Al Inc

Actions
  • Price (USD)0.4905
  • Today's Change-0.020 / -3.96%
  • Shares traded113.64k
  • 1 Year change-58.08%
  • Beta-1.0391
Data delayed at least 15 minutes, as of Feb 13 2026 20:54 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Healwell Al Inc. is a Canada-based healthcare artificial intelligence (AI) company focused on preventative care. The Company, using its own proprietary technology, is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases. The Company's segments include Clinical Research and Patient services, AI and Data sciences and Healthcare Software. The Clinical Research and Patient Services segment includes clinical research contracts and medical consultations provided through the Company's MCI Polyclinic Group Inc. and BioPharma subsidiaries in Ontario. The AI and Data Sciences segment includes integration of advanced AI and data science technologies in healthcare through its Khure Health Inc. and Pentavere and Mutuo subsidiaries. The Healthcare Software segment includes Intrahealth and Versource healthcare software-as-a-service.

  • Revenue in CAD (TTM)100.17m
  • Net income in CAD-47.21m
  • Incorporated2020
  • Employees350.00
  • Location
    Healwell Al Inc4881 Yonge Street, Suite 300Toronto M2N5X3CanadaCAN
  • Phone+1 (905) 960-6717
  • Websitehttps://healwell.ai/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.